Inhibikase: Results from its Phase 1 Parkinson's Studies

 Data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volunteers or worsening of symptoms in participants taking anti-PD medications

 Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced a publication of Phase 1 clinical studies with risvodetinib (“risvo”), a potential disease-modifying therapy for Parkinson’s disease and related disorders. The publication entitled “A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson’s Disease” was published online in the peer reviewed Journal of Parkinson’s Disease (DOI: 10.3233/JPD-230319) on January 13, 2024.

https://www.biospace.com/article/releases/inhibikase-therapeutics-announces-publication-highlighting-results-from-its-phase-1-studies-with-risvodetinib/